- Planning and Evaluation The CFCCC Director has a wide array of advisory input to assist in planning for the Center's future and evaluating the outcomes of Center programs and policy implementation. The most important of these is the day-to-day decision-making body, the Senior Leadership Council, which convenes bi-weekly. This group consists of the traditional senior leaders of the Center, including the Director, the Deputy Director and the Associate Directors, as well as several other key senior members of the Center. All plans either originate in or pass through this group. Both the External Scientific Advisory Board and the Internal Advisory Board (each meeting annually) continue to play a significant role in reviewing our plans and advising on our course of action. Program Leaders convene on a monthly basis and are joined quarterly by the Shared Resource Directors. Our ongoing annual full Cancer Center Scientific Retreat is critical for promoting and facilitating key collaborations. Additionally, the CFCCC organizes regular retreats and other events designed to stimulate interdisciplinary research opportunities and conducts regular assessments of research progress, interactions, membership participation, and future directions of the Research Programs. Strategic planning is a dynamic process that is informally woven into the structure of each of our senior committees, both internal and external. In addition, the CFCCC regularly engages in a formal strategic planning process, with a new Strategic Plan being completed in early 2015. Performance and progress of the stated goals within the Strategic Plan are tracked and catalogued on an ongoing basis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA062203-23
Application #
9851353
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-02-01
Budget End
2021-01-31
Support Year
23
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California Irvine
Department
Type
DUNS #
046705849
City
Irvine
State
CA
Country
United States
Zip Code
92617
Chakraborty, Mahul; VanKuren, Nicholas W; Zhao, Roy et al. (2018) Hidden genetic variation shapes the structure of functional elements in Drosophila. Nat Genet 50:20-25
Morozko, Eva L; Ochaba, Joseph; Hernandez, Sarah J et al. (2018) Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice. J Huntingtons Dis 7:321-335
Carpenter, Philip M; Ziogas, Argyrios; Markham, Emma M et al. (2018) Laminin 332 expression and prognosis in breast cancer. Hum Pathol 82:289-296
Yan, Huaming; Romero-López, Mónica; Benitez, Lesly I et al. (2018) Multiscale modeling of glioblastoma. Transl Cancer Res 7:S96-S98
Yu, James; Landberg, Jenny; Shavarebi, Farbod et al. (2018) Bioengineering triacetic acid lactone production in Yarrowia lipolytica for pogostone synthesis. Biotechnol Bioeng 115:2383-2388
Oliver, Andrew; Kay, Matthew; Cooper, Kerry K (2018) Comparative genomics of cocci-shaped Sporosarcina strains with diverse spatial isolation. BMC Genomics 19:310
Mahlbacher, Grace; Curtis, Louis T; Lowengrub, John et al. (2018) Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment. J Immunother Cancer 6:10
Neek, Medea; Tucker, Jo Anne; Kim, Tae Il et al. (2018) Co-delivery of human cancer-testis antigens with adjuvant in protein nanoparticles induces higher cell-mediated immune responses. Biomaterials 156:194-203
McLelland, Bryce T; Lin, Bin; Mathur, Anuradha et al. (2018) Transplanted hESC-Derived Retina Organoid Sheets Differentiate, Integrate, and Improve Visual Function in Retinal Degenerate Rats. Invest Ophthalmol Vis Sci 59:2586-2603
Bota, Daniela A; Chung, Jinah; Dandekar, Manisha et al. (2018) Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts. CNS Oncol 7:CNS22

Showing the most recent 10 out of 1106 publications